These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 37022618)
1. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better? Haist M; Stege H; Kuske M; Bauer J; Klumpp A; Grabbe S; Bros M Cancer Metastasis Rev; 2023 Jun; 42(2):481-505. PubMed ID: 37022618 [TBL] [Abstract][Full Text] [Related]
2. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322 [TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE Front Immunol; 2021; 12():661737. PubMed ID: 34025662 [TBL] [Abstract][Full Text] [Related]
5. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. Dummer R; Ascierto PA; Nathan P; Robert C; Schadendorf D JAMA Oncol; 2020 Dec; 6(12):1957-1966. PubMed ID: 32970096 [TBL] [Abstract][Full Text] [Related]
6. BRAF inhibitors and their immunological effects in malignant melanoma. Adams R; Coumbe JEM; Coumbe BGT; Thomas J; Willsmore Z; Dimitrievska M; Yasuzawa-Parker M; Hoyle M; Ingar S; Geh JLC; MacKenzie Ross AD; Healy C; Papa S; Lacy KE; Karagiannis SN Expert Rev Clin Immunol; 2022 Apr; 18(4):347-362. PubMed ID: 35195495 [TBL] [Abstract][Full Text] [Related]
7. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy? Kelley MC Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005 [TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy. Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328 [TBL] [Abstract][Full Text] [Related]
9. Plasma proteome alterations by MAPK inhibitors in BRAF Babačić H; Eriksson H; Pernemalm M Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure? Schummer P; Schilling B; Gesierich A Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332 [TBL] [Abstract][Full Text] [Related]
11. Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients. Ferrucci PF; Lens M; Cocorocchio E Curr Oncol Rep; 2021 Nov; 23(12):138. PubMed ID: 34735635 [TBL] [Abstract][Full Text] [Related]
12. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data. Wu B; Shi L JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281 [TBL] [Abstract][Full Text] [Related]
13. Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights. Awada G; Neyns B Curr Opin Oncol; 2022 Mar; 34(2):115-122. PubMed ID: 35050937 [TBL] [Abstract][Full Text] [Related]